nodes	percent_of_prediction	percent_of_DWPC	metapath
Aminosalicylic Acid—L-DOPA—Melphalan—ovarian cancer	0.497	1	CrCrCtD
Aminosalicylic Acid—MPO—Carboplatin—ovarian cancer	0.178	1	CbGbCtD
Aminosalicylic Acid—PTGS2—ovarian follicle—ovarian cancer	0.00697	0.145	CbGeAlD
Aminosalicylic Acid—Cutaneous hypersensitivity—Melphalan—ovarian cancer	0.00544	0.0453	CcSEcCtD
Aminosalicylic Acid—Lymphoma—Melphalan—ovarian cancer	0.0038	0.0317	CcSEcCtD
Aminosalicylic Acid—Non-Hodgkin's lymphoma—Melphalan—ovarian cancer	0.0038	0.0317	CcSEcCtD
Aminosalicylic Acid—CHUK—epithelium—ovarian cancer	0.00356	0.074	CbGeAlD
Aminosalicylic Acid—PTGS1—oviduct—ovarian cancer	0.0032	0.0666	CbGeAlD
Aminosalicylic Acid—Cutaneous hypersensitivity—Docetaxel—ovarian cancer	0.00271	0.0226	CcSEcCtD
Aminosalicylic Acid—CHUK—female reproductive system—ovarian cancer	0.00264	0.055	CbGeAlD
Aminosalicylic Acid—CHUK—female gonad—ovarian cancer	0.0024	0.05	CbGeAlD
Aminosalicylic Acid—Neuropathy peripheral—Altretamine—ovarian cancer	0.00235	0.0196	CcSEcCtD
Aminosalicylic Acid—CHUK—testis—ovarian cancer	0.00213	0.0444	CbGeAlD
Aminosalicylic Acid—Dermatitis atopic—Chlorambucil—ovarian cancer	0.00206	0.0172	CcSEcCtD
Aminosalicylic Acid—ALOX5—decidua—ovarian cancer	0.00189	0.0394	CbGeAlD
Aminosalicylic Acid—Dermatitis atopic—Melphalan—ovarian cancer	0.0018	0.015	CcSEcCtD
Aminosalicylic Acid—Anaemia—Altretamine—ovarian cancer	0.00173	0.0144	CcSEcCtD
Aminosalicylic Acid—MPO—epithelium—ovarian cancer	0.0017	0.0353	CbGeAlD
Aminosalicylic Acid—Leukopenia—Altretamine—ovarian cancer	0.00168	0.014	CcSEcCtD
Aminosalicylic Acid—CHUK—lymph node—ovarian cancer	0.00155	0.0322	CbGeAlD
Aminosalicylic Acid—Thrombocytopenia—Altretamine—ovarian cancer	0.0015	0.0125	CcSEcCtD
Aminosalicylic Acid—ALOX5—female reproductive system—ovarian cancer	0.00149	0.031	CbGeAlD
Aminosalicylic Acid—Anorexia—Altretamine—ovarian cancer	0.00146	0.0121	CcSEcCtD
Aminosalicylic Acid—ALOX5—bone marrow—ovarian cancer	0.00141	0.0292	CbGeAlD
Aminosalicylic Acid—Vasculitis—Melphalan—ovarian cancer	0.00136	0.0113	CcSEcCtD
Aminosalicylic Acid—ALOX5—female gonad—ovarian cancer	0.00135	0.0282	CbGeAlD
Aminosalicylic Acid—Decreased appetite—Altretamine—ovarian cancer	0.00133	0.0111	CcSEcCtD
Aminosalicylic Acid—Haemolytic anaemia—Chlorambucil—ovarian cancer	0.00123	0.0102	CcSEcCtD
Aminosalicylic Acid—Encephalopathy—Paclitaxel—ovarian cancer	0.00122	0.0101	CcSEcCtD
Aminosalicylic Acid—ALOX5—testis—ovarian cancer	0.0012	0.025	CbGeAlD
Aminosalicylic Acid—MPO—bone marrow—ovarian cancer	0.00119	0.0247	CbGeAlD
Aminosalicylic Acid—Eruption—Docetaxel—ovarian cancer	0.00108	0.00896	CcSEcCtD
Aminosalicylic Acid—Haemolytic anaemia—Melphalan—ovarian cancer	0.00107	0.0089	CcSEcCtD
Aminosalicylic Acid—Dermatitis atopic—Paclitaxel—ovarian cancer	0.00106	0.00879	CcSEcCtD
Aminosalicylic Acid—Pericarditis—Epirubicin—ovarian cancer	0.00103	0.0086	CcSEcCtD
Aminosalicylic Acid—MPO—testis—ovarian cancer	0.00102	0.0211	CbGeAlD
Aminosalicylic Acid—Dizziness—Altretamine—ovarian cancer	0.00101	0.00843	CcSEcCtD
Aminosalicylic Acid—PTGS2—myometrium—ovarian cancer	0.000979	0.0204	CbGeAlD
Aminosalicylic Acid—Vomiting—Altretamine—ovarian cancer	0.000973	0.0081	CcSEcCtD
Aminosalicylic Acid—Pericarditis—Doxorubicin—ovarian cancer	0.000956	0.00795	CcSEcCtD
Aminosalicylic Acid—PTGS2—embryo—ovarian cancer	0.000942	0.0196	CbGeAlD
Aminosalicylic Acid—Nausea—Altretamine—ovarian cancer	0.000909	0.00757	CcSEcCtD
Aminosalicylic Acid—Dermatitis atopic—Docetaxel—ovarian cancer	0.000895	0.00745	CcSEcCtD
Aminosalicylic Acid—ALOX5—lymph node—ovarian cancer	0.000871	0.0181	CbGeAlD
Aminosalicylic Acid—Neuropathy peripheral—Chlorambucil—ovarian cancer	0.000836	0.00696	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Carboplatin—ovarian cancer	0.000836	0.00696	CcSEcCtD
Aminosalicylic Acid—Jaundice—Chlorambucil—ovarian cancer	0.000832	0.00692	CcSEcCtD
Aminosalicylic Acid—PTGS1—epithelium—ovarian cancer	0.000804	0.0167	CbGeAlD
Aminosalicylic Acid—PTGS1—uterine cervix—ovarian cancer	0.000797	0.0166	CbGeAlD
Aminosalicylic Acid—PTGS2—epithelium—ovarian cancer	0.000769	0.016	CbGeAlD
Aminosalicylic Acid—PTGS2—uterine cervix—ovarian cancer	0.000762	0.0159	CbGeAlD
Aminosalicylic Acid—Neuropathy peripheral—Topotecan—ovarian cancer	0.000744	0.0062	CcSEcCtD
Aminosalicylic Acid—MPO—lymph node—ovarian cancer	0.000737	0.0153	CbGeAlD
Aminosalicylic Acid—Neuropathy peripheral—Melphalan—ovarian cancer	0.000729	0.00607	CcSEcCtD
Aminosalicylic Acid—Eruption—Epirubicin—ovarian cancer	0.000726	0.00604	CcSEcCtD
Aminosalicylic Acid—Optic neuritis—Epirubicin—ovarian cancer	0.000726	0.00604	CcSEcCtD
Aminosalicylic Acid—Jaundice—Melphalan—ovarian cancer	0.000725	0.00603	CcSEcCtD
Aminosalicylic Acid—PTGS1—endometrium—ovarian cancer	0.000721	0.015	CbGeAlD
Aminosalicylic Acid—PTGS2—endometrium—ovarian cancer	0.000689	0.0143	CbGeAlD
Aminosalicylic Acid—Eruption—Doxorubicin—ovarian cancer	0.000672	0.00559	CcSEcCtD
Aminosalicylic Acid—Optic neuritis—Doxorubicin—ovarian cancer	0.000672	0.00559	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Melphalan—ovarian cancer	0.000668	0.00556	CcSEcCtD
Aminosalicylic Acid—PTGS1—uterus—ovarian cancer	0.000665	0.0138	CbGeAlD
Aminosalicylic Acid—Urinary tract disorder—Melphalan—ovarian cancer	0.000659	0.00549	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Vinorelbine—ovarian cancer	0.000659	0.00549	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Melphalan—ovarian cancer	0.000654	0.00545	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Vinorelbine—ovarian cancer	0.000637	0.0053	CcSEcCtD
Aminosalicylic Acid—PTGS2—uterus—ovarian cancer	0.000635	0.0132	CbGeAlD
Aminosalicylic Acid—Anaemia—Chlorambucil—ovarian cancer	0.000616	0.00513	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Vinorelbine—ovarian cancer	0.000606	0.00505	CcSEcCtD
Aminosalicylic Acid—Dermatitis atopic—Epirubicin—ovarian cancer	0.000603	0.00502	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Paclitaxel—ovarian cancer	0.000601	0.005	CcSEcCtD
Aminosalicylic Acid—PTGS1—female reproductive system—ovarian cancer	0.000597	0.0124	CbGeAlD
Aminosalicylic Acid—Leukopenia—Chlorambucil—ovarian cancer	0.000597	0.00497	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Topotecan—ovarian cancer	0.000594	0.00494	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Paclitaxel—ovarian cancer	0.000581	0.00484	CcSEcCtD
Aminosalicylic Acid—PTGS2—female reproductive system—ovarian cancer	0.000571	0.0119	CbGeAlD
Aminosalicylic Acid—Dermatitis atopic—Doxorubicin—ovarian cancer	0.000558	0.00465	CcSEcCtD
Aminosalicylic Acid—Anaemia—Topotecan—ovarian cancer	0.000549	0.00457	CcSEcCtD
Aminosalicylic Acid—PTGS1—female gonad—ovarian cancer	0.000544	0.0113	CbGeAlD
Aminosalicylic Acid—PTGS1—vagina—ovarian cancer	0.00054	0.0112	CbGeAlD
Aminosalicylic Acid—PTGS2—bone marrow—ovarian cancer	0.000539	0.0112	CbGeAlD
Aminosalicylic Acid—Anaemia—Melphalan—ovarian cancer	0.000537	0.00447	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000533	0.00443	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Topotecan—ovarian cancer	0.000531	0.00442	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Melphalan—ovarian cancer	0.00052	0.00433	CcSEcCtD
Aminosalicylic Acid—PTGS2—female gonad—ovarian cancer	0.00052	0.0108	CbGeAlD
Aminosalicylic Acid—Anorexia—Chlorambucil—ovarian cancer	0.000519	0.00432	CcSEcCtD
Aminosalicylic Acid—PTGS2—vagina—ovarian cancer	0.000516	0.0107	CbGeAlD
Aminosalicylic Acid—Malnutrition—Vinorelbine—ovarian cancer	0.000508	0.00423	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000502	0.00418	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Paclitaxel—ovarian cancer	0.000493	0.00411	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000491	0.00409	CcSEcCtD
Aminosalicylic Acid—PTGS1—testis—ovarian cancer	0.000482	0.01	CbGeAlD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Docetaxel—ovarian cancer	0.000481	0.004	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Topotecan—ovarian cancer	0.000475	0.00395	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Topotecan—ovarian cancer	0.000474	0.00395	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Chlorambucil—ovarian cancer	0.000473	0.00394	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Topotecan—ovarian cancer	0.000471	0.00392	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00047	0.00391	CcSEcCtD
Aminosalicylic Acid—Anaemia—Vinorelbine—ovarian cancer	0.000469	0.00391	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Melphalan—ovarian cancer	0.000464	0.00387	CcSEcCtD
Aminosalicylic Acid—Anorexia—Topotecan—ovarian cancer	0.000462	0.00384	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Melphalan—ovarian cancer	0.000461	0.00383	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Vinorelbine—ovarian cancer	0.000454	0.00378	CcSEcCtD
Aminosalicylic Acid—Anorexia—Melphalan—ovarian cancer	0.000452	0.00376	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000445	0.0037	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Paclitaxel—ovarian cancer	0.000443	0.00369	CcSEcCtD
Aminosalicylic Acid—Urticaria—Chlorambucil—ovarian cancer	0.000432	0.0036	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Chlorambucil—ovarian cancer	0.00043	0.00358	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Chlorambucil—ovarian cancer	0.00043	0.00358	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000429	0.00357	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Paclitaxel—ovarian cancer	0.000428	0.00357	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Topotecan—ovarian cancer	0.000421	0.00351	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000418	0.00348	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Melphalan—ovarian cancer	0.000412	0.00343	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000409	0.00341	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Vinorelbine—ovarian cancer	0.000406	0.00338	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000406	0.00338	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Vinorelbine—ovarian cancer	0.000402	0.00335	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Chlorambucil—ovarian cancer	0.000401	0.00334	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Topotecan—ovarian cancer	0.000396	0.0033	CcSEcCtD
Aminosalicylic Acid—Anorexia—Vinorelbine—ovarian cancer	0.000395	0.00329	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000387	0.00322	CcSEcCtD
Aminosalicylic Acid—Urticaria—Topotecan—ovarian cancer	0.000385	0.0032	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Paclitaxel—ovarian cancer	0.000385	0.0032	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Topotecan—ovarian cancer	0.000383	0.00319	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Topotecan—ovarian cancer	0.000383	0.00319	CcSEcCtD
Aminosalicylic Acid—Urticaria—Melphalan—ovarian cancer	0.000377	0.00314	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Docetaxel—ovarian cancer	0.000376	0.00313	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Chlorambucil—ovarian cancer	0.000372	0.0031	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000363	0.00302	CcSEcCtD
Aminosalicylic Acid—Vascular purpura—Epirubicin—ovarian cancer	0.000362	0.00302	CcSEcCtD
Aminosalicylic Acid—Jaundice—Docetaxel—ovarian cancer	0.000361	0.00301	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Vinorelbine—ovarian cancer	0.00036	0.003	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000358	0.00298	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Topotecan—ovarian cancer	0.000357	0.00297	CcSEcCtD
Aminosalicylic Acid—PTGS1—lymph node—ovarian cancer	0.00035	0.00727	CbGeAlD
Aminosalicylic Acid—Hypersensitivity—Melphalan—ovarian cancer	0.000349	0.00291	CcSEcCtD
Aminosalicylic Acid—Vomiting—Chlorambucil—ovarian cancer	0.000346	0.00288	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Docetaxel—ovarian cancer	0.000346	0.00288	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.000344	0.00286	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Paclitaxel—ovarian cancer	0.000342	0.00284	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000339	0.00282	CcSEcCtD
Aminosalicylic Acid—Flatulence—Paclitaxel—ovarian cancer	0.000337	0.0028	CcSEcCtD
Aminosalicylic Acid—Purpura—Epirubicin—ovarian cancer	0.000336	0.0028	CcSEcCtD
Aminosalicylic Acid—Vascular purpura—Doxorubicin—ovarian cancer	0.000335	0.00279	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Paclitaxel—ovarian cancer	0.000334	0.00278	CcSEcCtD
Aminosalicylic Acid—PTGS2—lymph node—ovarian cancer	0.000334	0.00695	CbGeAlD
Aminosalicylic Acid—Hepatitis—Docetaxel—ovarian cancer	0.000333	0.00277	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Epirubicin—ovarian cancer	0.000332	0.00277	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Topotecan—ovarian cancer	0.000331	0.00276	CcSEcCtD
Aminosalicylic Acid—Urticaria—Vinorelbine—ovarian cancer	0.000329	0.00274	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Docetaxel—ovarian cancer	0.000328	0.00273	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Vinorelbine—ovarian cancer	0.000328	0.00273	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Vinorelbine—ovarian cancer	0.000328	0.00273	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Docetaxel—ovarian cancer	0.000326	0.00271	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Melphalan—ovarian cancer	0.000325	0.0027	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.000324	0.0027	CcSEcCtD
Aminosalicylic Acid—Nausea—Chlorambucil—ovarian cancer	0.000323	0.00269	CcSEcCtD
Aminosalicylic Acid—Dizziness—Topotecan—ovarian cancer	0.00032	0.00267	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.000318	0.00265	CcSEcCtD
Aminosalicylic Acid—Anaemia—Paclitaxel—ovarian cancer	0.000316	0.00263	CcSEcCtD
Aminosalicylic Acid—Purpura—Doxorubicin—ovarian cancer	0.000311	0.00259	CcSEcCtD
Aminosalicylic Acid—Vomiting—Topotecan—ovarian cancer	0.000308	0.00256	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000307	0.00256	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Paclitaxel—ovarian cancer	0.000306	0.00254	CcSEcCtD
Aminosalicylic Acid—Rash—Topotecan—ovarian cancer	0.000305	0.00254	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Vinorelbine—ovarian cancer	0.000305	0.00254	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Topotecan—ovarian cancer	0.000305	0.00254	CcSEcCtD
Aminosalicylic Acid—Headache—Topotecan—ovarian cancer	0.000303	0.00253	CcSEcCtD
Aminosalicylic Acid—Vomiting—Melphalan—ovarian cancer	0.000302	0.00251	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.0003	0.0025	CcSEcCtD
Aminosalicylic Acid—Rash—Melphalan—ovarian cancer	0.000299	0.00249	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Melphalan—ovarian cancer	0.000299	0.00249	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Docetaxel—ovarian cancer	0.000289	0.00241	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000289	0.0024	CcSEcCtD
Aminosalicylic Acid—Nausea—Topotecan—ovarian cancer	0.000288	0.00239	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Vinorelbine—ovarian cancer	0.000284	0.00236	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Docetaxel—ovarian cancer	0.000283	0.00236	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Epirubicin—ovarian cancer	0.000282	0.00235	CcSEcCtD
Aminosalicylic Acid—Nausea—Melphalan—ovarian cancer	0.000282	0.00235	CcSEcCtD
Aminosalicylic Acid—Dizziness—Vinorelbine—ovarian cancer	0.000274	0.00228	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Paclitaxel—ovarian cancer	0.000273	0.00228	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000273	0.00227	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Paclitaxel—ovarian cancer	0.000271	0.00225	CcSEcCtD
Aminosalicylic Acid—Anaemia—Docetaxel—ovarian cancer	0.000268	0.00223	CcSEcCtD
Aminosalicylic Acid—Anorexia—Paclitaxel—ovarian cancer	0.000266	0.00221	CcSEcCtD
Aminosalicylic Acid—Vomiting—Vinorelbine—ovarian cancer	0.000263	0.00219	CcSEcCtD
Aminosalicylic Acid—Rash—Vinorelbine—ovarian cancer	0.000261	0.00217	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Vinorelbine—ovarian cancer	0.000261	0.00217	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Doxorubicin—ovarian cancer	0.000261	0.00217	CcSEcCtD
Aminosalicylic Acid—Headache—Vinorelbine—ovarian cancer	0.00026	0.00216	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Docetaxel—ovarian cancer	0.000259	0.00216	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Epirubicin—ovarian cancer	0.000254	0.00211	CcSEcCtD
Aminosalicylic Acid—Nausea—Vinorelbine—ovarian cancer	0.000246	0.00205	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000245	0.00204	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000245	0.00204	CcSEcCtD
Aminosalicylic Acid—Jaundice—Epirubicin—ovarian cancer	0.000244	0.00203	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Paclitaxel—ovarian cancer	0.000242	0.00202	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000241	0.002	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Doxorubicin—ovarian cancer	0.000235	0.00195	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Epirubicin—ovarian cancer	0.000233	0.00194	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Docetaxel—ovarian cancer	0.000232	0.00193	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Docetaxel—ovarian cancer	0.000231	0.00193	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Docetaxel—ovarian cancer	0.000229	0.00191	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000228	0.0019	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000227	0.00189	CcSEcCtD
Aminosalicylic Acid—Jaundice—Doxorubicin—ovarian cancer	0.000225	0.00188	CcSEcCtD
Aminosalicylic Acid—Anorexia—Docetaxel—ovarian cancer	0.000225	0.00187	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Epirubicin—ovarian cancer	0.000224	0.00187	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Epirubicin—ovarian cancer	0.000221	0.00184	CcSEcCtD
Aminosalicylic Acid—Urticaria—Paclitaxel—ovarian cancer	0.000221	0.00184	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Paclitaxel—ovarian cancer	0.00022	0.00183	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Paclitaxel—ovarian cancer	0.00022	0.00183	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Epirubicin—ovarian cancer	0.00022	0.00183	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Doxorubicin—ovarian cancer	0.000216	0.0018	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Doxorubicin—ovarian cancer	0.000208	0.00173	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Docetaxel—ovarian cancer	0.000205	0.00171	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Paclitaxel—ovarian cancer	0.000205	0.00171	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000205	0.00171	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000204	0.0017	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Doxorubicin—ovarian cancer	0.000203	0.00169	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Epirubicin—ovarian cancer	0.000195	0.00163	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000193	0.00161	CcSEcCtD
Aminosalicylic Acid—Flatulence—Epirubicin—ovarian cancer	0.000192	0.0016	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Epirubicin—ovarian cancer	0.000191	0.00159	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Paclitaxel—ovarian cancer	0.000191	0.00159	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Docetaxel—ovarian cancer	0.000187	0.00155	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Docetaxel—ovarian cancer	0.000187	0.00155	CcSEcCtD
Aminosalicylic Acid—Dizziness—Paclitaxel—ovarian cancer	0.000184	0.00153	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Doxorubicin—ovarian cancer	0.000181	0.0015	CcSEcCtD
Aminosalicylic Acid—Anaemia—Epirubicin—ovarian cancer	0.00018	0.0015	CcSEcCtD
Aminosalicylic Acid—Flatulence—Doxorubicin—ovarian cancer	0.000178	0.00148	CcSEcCtD
Aminosalicylic Acid—Vomiting—Paclitaxel—ovarian cancer	0.000177	0.00148	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Doxorubicin—ovarian cancer	0.000177	0.00147	CcSEcCtD
Aminosalicylic Acid—Rash—Paclitaxel—ovarian cancer	0.000176	0.00146	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Paclitaxel—ovarian cancer	0.000176	0.00146	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Epirubicin—ovarian cancer	0.000175	0.00145	CcSEcCtD
Aminosalicylic Acid—Headache—Paclitaxel—ovarian cancer	0.000175	0.00145	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Docetaxel—ovarian cancer	0.000174	0.00145	CcSEcCtD
Aminosalicylic Acid—Anaemia—Doxorubicin—ovarian cancer	0.000167	0.00139	CcSEcCtD
Aminosalicylic Acid—Nausea—Paclitaxel—ovarian cancer	0.000166	0.00138	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000165	0.00137	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Doxorubicin—ovarian cancer	0.000162	0.00135	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Docetaxel—ovarian cancer	0.000162	0.00135	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Epirubicin—ovarian cancer	0.000156	0.0013	CcSEcCtD
Aminosalicylic Acid—Dizziness—Docetaxel—ovarian cancer	0.000156	0.0013	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Epirubicin—ovarian cancer	0.000156	0.0013	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Epirubicin—ovarian cancer	0.000155	0.00129	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000153	0.00127	CcSEcCtD
Aminosalicylic Acid—Anorexia—Epirubicin—ovarian cancer	0.000152	0.00126	CcSEcCtD
Aminosalicylic Acid—Vomiting—Docetaxel—ovarian cancer	0.00015	0.00125	CcSEcCtD
Aminosalicylic Acid—Rash—Docetaxel—ovarian cancer	0.000149	0.00124	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Docetaxel—ovarian cancer	0.000149	0.00124	CcSEcCtD
Aminosalicylic Acid—Headache—Docetaxel—ovarian cancer	0.000148	0.00123	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Doxorubicin—ovarian cancer	0.000145	0.0012	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000144	0.0012	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Doxorubicin—ovarian cancer	0.000143	0.00119	CcSEcCtD
Aminosalicylic Acid—Anorexia—Doxorubicin—ovarian cancer	0.000141	0.00117	CcSEcCtD
Aminosalicylic Acid—Nausea—Docetaxel—ovarian cancer	0.00014	0.00117	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Epirubicin—ovarian cancer	0.000139	0.00115	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000138	0.00115	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00013	0.00108	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Doxorubicin—ovarian cancer	0.000128	0.00107	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000127	0.00106	CcSEcCtD
Aminosalicylic Acid—Urticaria—Epirubicin—ovarian cancer	0.000127	0.00105	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Epirubicin—ovarian cancer	0.000126	0.00105	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Epirubicin—ovarian cancer	0.000126	0.00105	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000121	0.001	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Epirubicin—ovarian cancer	0.000117	0.000977	CcSEcCtD
Aminosalicylic Acid—Urticaria—Doxorubicin—ovarian cancer	0.000117	0.000975	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Doxorubicin—ovarian cancer	0.000117	0.00097	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Doxorubicin—ovarian cancer	0.000117	0.00097	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Epirubicin—ovarian cancer	0.000109	0.000908	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Doxorubicin—ovarian cancer	0.000109	0.000904	CcSEcCtD
Aminosalicylic Acid—Dizziness—Epirubicin—ovarian cancer	0.000105	0.000877	CcSEcCtD
Aminosalicylic Acid—Vomiting—Epirubicin—ovarian cancer	0.000101	0.000843	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Doxorubicin—ovarian cancer	0.000101	0.00084	CcSEcCtD
Aminosalicylic Acid—Rash—Epirubicin—ovarian cancer	0.0001	0.000836	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Epirubicin—ovarian cancer	0.0001	0.000836	CcSEcCtD
Aminosalicylic Acid—Headache—Epirubicin—ovarian cancer	9.98e-05	0.000831	CcSEcCtD
Aminosalicylic Acid—Dizziness—Doxorubicin—ovarian cancer	9.75e-05	0.000812	CcSEcCtD
Aminosalicylic Acid—Nausea—Epirubicin—ovarian cancer	9.46e-05	0.000788	CcSEcCtD
Aminosalicylic Acid—Vomiting—Doxorubicin—ovarian cancer	9.37e-05	0.00078	CcSEcCtD
Aminosalicylic Acid—Rash—Doxorubicin—ovarian cancer	9.3e-05	0.000774	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Doxorubicin—ovarian cancer	9.29e-05	0.000773	CcSEcCtD
Aminosalicylic Acid—Headache—Doxorubicin—ovarian cancer	9.24e-05	0.000769	CcSEcCtD
Aminosalicylic Acid—Nausea—Doxorubicin—ovarian cancer	8.76e-05	0.000729	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by PDGF—IL6—ovarian cancer	3.7e-05	0.000236	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—IL6ST—ovarian cancer	3.69e-05	0.000236	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—STAT3—ovarian cancer	3.69e-05	0.000235	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—NRAS—ovarian cancer	3.68e-05	0.000235	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CYTB—ovarian cancer	3.67e-05	0.000234	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.66e-05	0.000234	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—HRAS—ovarian cancer	3.65e-05	0.000233	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—ovarian cancer	3.65e-05	0.000233	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3.59e-05	0.000229	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.58e-05	0.000229	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—MAPK3—ovarian cancer	3.58e-05	0.000229	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—FASN—ovarian cancer	3.53e-05	0.000225	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—MAPK3—ovarian cancer	3.52e-05	0.000225	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PARP1—ovarian cancer	3.52e-05	0.000225	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—ovarian cancer	3.5e-05	0.000223	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	3.49e-05	0.000223	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—AKT1—ovarian cancer	3.49e-05	0.000223	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—AKT1—ovarian cancer	3.49e-05	0.000223	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—AKT1—ovarian cancer	3.49e-05	0.000223	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	3.46e-05	0.000221	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—AKT1—ovarian cancer	3.46e-05	0.000221	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—HDAC6—ovarian cancer	3.43e-05	0.000219	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—AKT1—ovarian cancer	3.42e-05	0.000219	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—AKT1—ovarian cancer	3.41e-05	0.000218	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—MAPK1—ovarian cancer	3.41e-05	0.000218	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	3.38e-05	0.000216	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.37e-05	0.000215	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—SLC2A1—ovarian cancer	3.35e-05	0.000214	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—MAPK1—ovarian cancer	3.35e-05	0.000214	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—EGFR—ovarian cancer	3.35e-05	0.000214	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—ovarian cancer	3.35e-05	0.000214	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.28e-05	0.000209	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—PIK3CA—ovarian cancer	3.28e-05	0.000209	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—AKT1—ovarian cancer	3.23e-05	0.000206	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—KRAS—ovarian cancer	3.22e-05	0.000206	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—BRIP1—ovarian cancer	3.2e-05	0.000205	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PPP1CC—ovarian cancer	3.2e-05	0.000205	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—KRAS—ovarian cancer	3.16e-05	0.000202	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CDH1—ovarian cancer	3.14e-05	0.0002	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—PIK3CD—ovarian cancer	3.12e-05	0.000199	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	3.1e-05	0.000198	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—PPP2R1A—ovarian cancer	3.09e-05	0.000197	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—AKT1—ovarian cancer	3.09e-05	0.000197	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.05e-05	0.000194	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—YAP1—ovarian cancer	3.03e-05	0.000194	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—CAV1—ovarian cancer	3.02e-05	0.000193	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—PIK3CD—ovarian cancer	3e-05	0.000191	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—XIAP—ovarian cancer	2.97e-05	0.00019	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—PIK3CA—ovarian cancer	2.96e-05	0.000189	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.94e-05	0.000188	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—PIK3CA—ovarian cancer	2.91e-05	0.000186	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—HDAC6—ovarian cancer	2.9e-05	0.000185	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—SMARCA4—ovarian cancer	2.9e-05	0.000185	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.89e-05	0.000184	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.88e-05	0.000184	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PPP2R1A—ovarian cancer	2.85e-05	0.000182	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—EREG—ovarian cancer	2.83e-05	0.00018	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.8e-05	0.000179	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—ERBB2—ovarian cancer	2.76e-05	0.000176	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CD8A—ovarian cancer	2.75e-05	0.000176	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PIK3CG—ovarian cancer	2.75e-05	0.000176	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.74e-05	0.000175	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.74e-05	0.000175	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—HRAS—ovarian cancer	2.74e-05	0.000175	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—PIK3CB—ovarian cancer	2.72e-05	0.000174	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—MTOR—ovarian cancer	2.72e-05	0.000174	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—YAP1—ovarian cancer	2.71e-05	0.000173	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—HRAS—ovarian cancer	2.69e-05	0.000172	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—AKT1—ovarian cancer	2.68e-05	0.000171	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.68e-05	0.000171	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PGR—ovarian cancer	2.65e-05	0.000169	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—ERBB2—ovarian cancer	2.65e-05	0.000169	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IL6—ovarian cancer	2.62e-05	0.000167	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—MTOR—ovarian cancer	2.61e-05	0.000167	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—PIK3CB—ovarian cancer	2.61e-05	0.000167	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.59e-05	0.000165	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—IL6—ovarian cancer	2.57e-05	0.000164	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—CDKN1B—ovarian cancer	2.55e-05	0.000163	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—XIAP—ovarian cancer	2.51e-05	0.00016	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PARP1—ovarian cancer	2.46e-05	0.000157	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CDKN1B—ovarian cancer	2.45e-05	0.000157	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—SMARCA4—ovarian cancer	2.45e-05	0.000156	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PIK3CD—ovarian cancer	2.42e-05	0.000154	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—CTNNB1—ovarian cancer	2.41e-05	0.000154	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—EREG—ovarian cancer	2.39e-05	0.000153	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.38e-05	0.000152	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—AKT1—ovarian cancer	2.38e-05	0.000152	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.35e-05	0.00015	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—PTEN—ovarian cancer	2.35e-05	0.00015	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.33e-05	0.000149	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.3e-05	0.000147	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—TERT—ovarian cancer	2.27e-05	0.000145	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—PTEN—ovarian cancer	2.26e-05	0.000144	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—TLR4—ovarian cancer	2.24e-05	0.000143	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—FASN—ovarian cancer	2.21e-05	0.000141	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—SLC5A5—ovarian cancer	2.17e-05	0.000139	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL6ST—ovarian cancer	2.15e-05	0.000137	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—YAP1—ovarian cancer	2.15e-05	0.000137	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.13e-05	0.000136	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PIK3CB—ovarian cancer	2.11e-05	0.000135	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—NRAS—ovarian cancer	2.1e-05	0.000134	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—SLC2A1—ovarian cancer	2.1e-05	0.000134	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CAV1—ovarian cancer	2.1e-05	0.000134	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—FASN—ovarian cancer	2.09e-05	0.000134	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PARP1—ovarian cancer	2.08e-05	0.000133	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.05e-05	0.000131	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—NRAS—ovarian cancer	2.01e-05	0.000129	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—CYP1B1—ovarian cancer	2.01e-05	0.000128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—MAPK3—ovarian cancer	2.01e-05	0.000128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PPP2R1A—ovarian cancer	2e-05	0.000128	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—SLC2A1—ovarian cancer	1.99e-05	0.000127	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—IL6ST—ovarian cancer	1.99e-05	0.000127	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.94e-05	0.000124	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—MAPK1—ovarian cancer	1.91e-05	0.000122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—EGFR—ovarian cancer	1.91e-05	0.000122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—APC—ovarian cancer	1.91e-05	0.000122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CDH1—ovarian cancer	1.9e-05	0.000121	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.87e-05	0.000119	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—EGFR—ovarian cancer	1.83e-05	0.000117	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PTEN—ovarian cancer	1.82e-05	0.000116	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—PIK3CD—ovarian cancer	1.82e-05	0.000116	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—KRAS—ovarian cancer	1.8e-05	0.000115	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PPP2R1A—ovarian cancer	1.78e-05	0.000114	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.77e-05	0.000113	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—FASN—ovarian cancer	1.75e-05	0.000112	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—KRAS—ovarian cancer	1.73e-05	0.000111	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—SLC5A5—ovarian cancer	1.72e-05	0.00011	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PPP2R1A—ovarian cancer	1.69e-05	0.000108	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PIK3CD—ovarian cancer	1.68e-05	0.000107	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—SLC2A1—ovarian cancer	1.66e-05	0.000106	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—PIK3CA—ovarian cancer	1.66e-05	0.000106	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—ABCB1—ovarian cancer	1.65e-05	0.000106	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.63e-05	0.000104	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—TYMS—ovarian cancer	1.63e-05	0.000104	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—ERBB2—ovarian cancer	1.61e-05	0.000103	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CYP1B1—ovarian cancer	1.6e-05	0.000102	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—PIK3CA—ovarian cancer	1.59e-05	0.000102	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TERT—ovarian cancer	1.59e-05	0.000101	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—PIK3CB—ovarian cancer	1.58e-05	0.000101	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—MTOR—ovarian cancer	1.58e-05	0.000101	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—HRAS—ovarian cancer	1.53e-05	9.8e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CDKN1B—ovarian cancer	1.49e-05	9.49e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—ERBB2—ovarian cancer	1.48e-05	9.46e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—HRAS—ovarian cancer	1.47e-05	9.41e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—IL6—ovarian cancer	1.47e-05	9.38e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CAV1—ovarian cancer	1.47e-05	9.37e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—MTOR—ovarian cancer	1.46e-05	9.34e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PIK3CB—ovarian cancer	1.46e-05	9.34e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL2—ovarian cancer	1.46e-05	9.29e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PPP2R1A—ovarian cancer	1.41e-05	9.03e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—ESR1—ovarian cancer	1.41e-05	9.03e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.41e-05	8.99e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CTNNB1—ovarian cancer	1.4e-05	8.97e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—IL6ST—ovarian cancer	1.39e-05	8.88e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CDKN1B—ovarian cancer	1.37e-05	8.76e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—PTEN—ovarian cancer	1.37e-05	8.74e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—AKT1—ovarian cancer	1.35e-05	8.65e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—TERT—ovarian cancer	1.34e-05	8.57e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PIK3CG—ovarian cancer	1.34e-05	8.54e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—APC—ovarian cancer	1.34e-05	8.54e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—ABCB1—ovarian cancer	1.31e-05	8.39e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—CAV1—ovarian cancer	1.31e-05	8.36e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—AKT1—ovarian cancer	1.3e-05	8.31e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CTNNB1—ovarian cancer	1.3e-05	8.28e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—TYMS—ovarian cancer	1.29e-05	8.24e-05	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PIK3CA—ovarian cancer	1.29e-05	8.21e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PTEN—ovarian cancer	1.26e-05	8.07e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.25e-05	7.99e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CAV1—ovarian cancer	1.24e-05	7.93e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—STAT3—ovarian cancer	1.22e-05	7.82e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—NRAS—ovarian cancer	1.22e-05	7.8e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PIK3CG—ovarian cancer	1.19e-05	7.62e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—IL6ST—ovarian cancer	1.18e-05	7.51e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PIK3CD—ovarian cancer	1.18e-05	7.5e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—MAPK3—ovarian cancer	1.17e-05	7.47e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—APC—ovarian cancer	1.13e-05	7.22e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—STAT3—ovarian cancer	1.13e-05	7.22e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—NRAS—ovarian cancer	1.13e-05	7.2e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—MAPK1—ovarian cancer	1.11e-05	7.11e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—EGFR—ovarian cancer	1.11e-05	7.11e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—MAPK3—ovarian cancer	1.08e-05	6.9e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—KRAS—ovarian cancer	1.05e-05	6.71e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—MYC—ovarian cancer	1.05e-05	6.71e-05	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—AKT1—ovarian cancer	1.05e-05	6.7e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PIK3CD—ovarian cancer	1.05e-05	6.7e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CAV1—ovarian cancer	1.04e-05	6.64e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—ERBB2—ovarian cancer	1.04e-05	6.63e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—MAPK1—ovarian cancer	1.03e-05	6.56e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—EGFR—ovarian cancer	1.03e-05	6.56e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MTOR—ovarian cancer	1.02e-05	6.54e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PIK3CB—ovarian cancer	1.02e-05	6.54e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PIK3CD—ovarian cancer	9.94e-06	6.35e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.93e-06	6.34e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CXCL8—ovarian cancer	9.84e-06	6.28e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—KRAS—ovarian cancer	9.71e-06	6.2e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—PIK3CA—ovarian cancer	9.66e-06	6.17e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CDKN1B—ovarian cancer	9.61e-06	6.14e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PIK3CG—ovarian cancer	9.47e-06	6.05e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CASP3—ovarian cancer	9.42e-06	6.02e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—IL2—ovarian cancer	9.41e-06	6.01e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CCND1—ovarian cancer	9.17e-06	5.86e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PIK3CB—ovarian cancer	9.14e-06	5.84e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CTNNB1—ovarian cancer	9.08e-06	5.8e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—HRAS—ovarian cancer	8.94e-06	5.71e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PIK3CA—ovarian cancer	8.92e-06	5.69e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MMP9—ovarian cancer	8.9e-06	5.68e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PTEN—ovarian cancer	8.85e-06	5.65e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—ERBB2—ovarian cancer	8.78e-06	5.61e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—MTOR—ovarian cancer	8.66e-06	5.53e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PIK3CB—ovarian cancer	8.66e-06	5.53e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL6—ovarian cancer	8.55e-06	5.46e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PIK3CD—ovarian cancer	8.33e-06	5.32e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—HRAS—ovarian cancer	8.25e-06	5.27e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CDKN1B—ovarian cancer	8.13e-06	5.19e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—VEGFA—ovarian cancer	7.99e-06	5.1e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—STAT3—ovarian cancer	7.92e-06	5.05e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PTEN—ovarian cancer	7.9e-06	5.04e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—NRAS—ovarian cancer	7.9e-06	5.04e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—IL6—ovarian cancer	7.9e-06	5.04e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—AKT1—ovarian cancer	7.89e-06	5.04e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CTNNB1—ovarian cancer	7.68e-06	4.9e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MAPK3—ovarian cancer	7.56e-06	4.83e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PTEN—ovarian cancer	7.49e-06	4.78e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MYC—ovarian cancer	7.36e-06	4.7e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—AKT1—ovarian cancer	7.28e-06	4.65e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PIK3CB—ovarian cancer	7.26e-06	4.63e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MAPK1—ovarian cancer	7.2e-06	4.59e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—EGFR—ovarian cancer	7.19e-06	4.59e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—KRAS—ovarian cancer	6.8e-06	4.34e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—STAT3—ovarian cancer	6.7e-06	4.28e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—NRAS—ovarian cancer	6.68e-06	4.27e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—MAPK3—ovarian cancer	6.4e-06	4.08e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PTEN—ovarian cancer	6.27e-06	4e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PIK3CA—ovarian cancer	6.24e-06	3.99e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—MYC—ovarian cancer	6.22e-06	3.97e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—MAPK1—ovarian cancer	6.09e-06	3.89e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—EGFR—ovarian cancer	6.09e-06	3.89e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TP53—ovarian cancer	6.04e-06	3.86e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—HRAS—ovarian cancer	5.78e-06	3.69e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—KRAS—ovarian cancer	5.75e-06	3.67e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PIK3CA—ovarian cancer	5.57e-06	3.56e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—IL6—ovarian cancer	5.53e-06	3.53e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PIK3CA—ovarian cancer	5.28e-06	3.37e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—AKT1—ovarian cancer	5.1e-06	3.26e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—HRAS—ovarian cancer	4.89e-06	3.12e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—IL6—ovarian cancer	4.68e-06	2.99e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—AKT1—ovarian cancer	4.55e-06	2.91e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PIK3CA—ovarian cancer	4.42e-06	2.82e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—AKT1—ovarian cancer	4.32e-06	2.76e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—AKT1—ovarian cancer	3.61e-06	2.31e-05	CbGpPWpGaD
